For Media Inquiries

Alisa Santiesteban, Director of Marketing & Communications
970-926-1277 /

Media Kit

    Can Do MS Receives Highest Recognition from Charity Navigator

    October 1st, 2019

    Thanks to its sound fiscal management practices and commitment to accountability and transparency, Can Do Multiple Sclerosis (Can Do MS) has earned a 4-star rating from Charity Navigator, America’s largest independent charity evaluator. 

    Continue Reading
    Can Do Multiple Sclerosis Announced as Benefactor for 11th Annual Man of the Cliff

    September 25th, 2019

    Man of the Cliff Returns to Avon's Nottingham Park October 12-13, 2019: Announces Can Do Multiple Sclerosis as Benefactor for 11th Annual Event

    Continue Reading
    ​What’s Top of Mind for People with Multiple Sclerosis?

    September 15th, 2019

    New Research from Can Do MS and EMD Serono Identifies Financial Planning and Staying in the Workplace as Critical Concerns in Managing Unpredictable Disease


    Continue Reading
    Support Can Do MS by buying Super Rad Raygun this month

    September 6th, 2019

    Independent game developers Chris Bryant and Chris Hernandez are raising money for families living with MS.  All revenue for Super Rad Raygun on during the month of September will be donated to Can Do MS!

    Continue Reading
    ​This September, show the world how you #KickMS to inspire others and spread awareness of multiple sclerosis

    September 3rd, 2019

    Can Do Multiple Sclerosis launched their annual, online campaign that encourages people living with MS, as well as their friends and supporters, to share how they thrive with MS during September’s Can Do Month celebration.

    Continue Reading
    Pro Cyclist Tyler Hamilton’s Annual MS Global Bike Tour Comes to Nova Scotia to Raise Funds for Multiple Sclerosis

    August 16th, 2019

    MS Global 2019, a seven-day annual charitable bicycle tour founded by former professional cyclist Tyler Hamilton to raise funds for families with multiple sclerosis (MS), will be held in Cape Breton Island, Nova Scotia from Sept. 14 to Sept. 22.

    Continue Reading
    FDA approves new oral drug to treat multiple sclerosis

    April 2nd, 2019

    The U.S. Food and Drug Administration approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

    Continue Reading
    FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis

    April 2nd, 2019

    EMD Serono announced that the U.S. Food and Drug Administration has approved MAVENCLAD® (cladribine) tablets for the treatment of adults with relapsing-remitting disease and active secondary progressive disease. 

    Continue Reading
    Lokai Launches Multiple Sclerosis Teal Bracelet

    March 4th, 2019

    Lokai, the socially responsible brand representing the importance of finding balance along life’s journey, announced a new teal bracelet in partnership with Can Do Multiple Sclerosis (Can Do MS).

    Continue Reading
    FDA Accepts BrainStorm’s NurOwn® IND Application for Progressive Multiple Sclerosis

    December 17th, 2018

    BrainStorm Cell Therapeutics Inc. announced that the U.S. Food and Drug Administration has accepted the Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of NurOwn® for the treatment of progressive multiple sclerosis.

    Continue Reading